Company news

The invention patent of CD47xVEGF mAb-Trap was authorized by China Intellectual Property Office

Date:2020-12-21 Views:341

On December 21, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that its CD47xVEGF MAb Trap (company project No.: IMM02) recently obtained the invention patent authorization from China Intellectual Property Office (China patent application No.: CN201580014639.8). Previously, the IMM02 project has obtained the invention patent authorization in the United States (US Patent No.: 14/666328), the European Union (EU patent No.: 15769704.6), Japan (Japan Patent No.: 2016-548031) and other countries and regions .

"At the same time, the bispecific antibody drugs targeting CD47 and VEGF have been granted invention patents in major global pharmaceutical markets such as China, the United States, the European Union and Japan, which once again fully reflects the strong R&D and innovation capabilities of the company's R&D team. The drug can inhibit the growth of tumor cells by inhibiting tumor neovascularization, making the tumor volume smaller; it can activate macrophages by blocking the CD47-SIRPα signal, which makes it easier to attack the shrunken and softened solid tumor." Dr. Tian Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, said: "IMM02 project is one of the many exciting projects in our pre-clinical development, which has significant anti-tumor activity in a variety of tumor models in preclinical research. We plan to speed up the research, actively promote the IMM02 project into the clinical stage, and benefit cancer patients as soon as possible."

About IMM02 project

IMM02 project is a bispecific antibody drug developed based on the "mAb-Trap" technology platform of ImmuneOnco and with independent intellectual property rights of ImmuneOnco. It targets CD47 and VEGF at the same time. The drug can act on tumor disease targets and regulate the immune system at the same time, and play a strong anti-tumor effect by inhibiting tumor vascular growth and activating macrophages.

About ImmuneOnco

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and TANKTM cell therapy. The common feature of our products is to stimulate and mobilize the immune system of patients to play an anti-tumor effect, and ultimately inhibit the continued growth of tumor cells, reverse a series of malignant symptoms caused by this, so that patients gradually return to a healthy state of the body.

Contact us

Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China

                Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China

Tel. + 86 21 5835 6573